Correlates of Breakthrough SARS-CoV-2 Infections in People with HIV: Results from the CIHR CTN 328 Study
Cecilia T. Costiniuk,Terry Lee,Joel Singer,Yannick Galipeau,Corey Arnold,Marc-André Langlois,Judy Needham,Mohammad-Ali Jenabian,Ann N. Burchell,Hasina Samji,Catharine Chambers,Sharon Walmsley,Mario Ostrowski,Colin Kovacs,Darrell H. S. Tan,Marianne Harris,Mark Hull,Zabrina L. Brumme,Hope R. Lapointe,Mark A. Brockman,Shari Margolese,Enrico Mandarino,Suzanne Samarani,Bertrand Lebouché,Jonathan B. Angel,Jean-Pierre Routy,Curtis L. Cooper,Aslam H. Anis
DOI: https://doi.org/10.3390/vaccines12050447
2024-04-24
Vaccines
Abstract:COVID-19 breakthrough infection (BTI) can occur despite vaccination. Using a multi-centre, prospective, observational Canadian cohort of people with HIV (PWH) receiving ≥2 COVID-19 vaccines, we compared the SARS-CoV-2 spike (S) and receptor-binding domain (RBD)-specific IgG levels 3 and 6 months post second dose, as well as 1 month post third dose, in PWH with and without BTI. BTI was defined as positivity based on self-report measures (data up to last study visit) or IgG data (up to 1 month post dose 3). The self-report measures were based on their symptoms and either a positive PCR or rapid antigen test. The analysis was restricted to persons without previous COVID-19 infection. Persons without BTI remained COVID-19-naïve until ≥3 months following the third dose. Of 289 participants, 92 developed BTI (31.5 infections per 100 person-years). The median days between last vaccination and BTI was 128 (IQR 67, 176), with the most cases occurring between the third and fourth dose (n = 59), corresponding to the Omicron wave. In analyses adjusted for age, sex, race, multimorbidity, hypertension, chronic kidney disease, diabetes and obesity, a lower IgG S/RBD (log10 BAU/mL) at 1 month post dose 3 was significantly associated with BTI, suggesting that a lower IgG level at this time point may predict BTI in this cohort of PWH.
immunology,medicine, research & experimental